Heidi Colton

Heidi Colton has a strong background in toxicology and nonclinical development strategy. Heidi has held various executive and senior director roles at Chimerix, Inc., where they designed and managed animal pharmacology studies, analyzed data for clinical dosing strategies, and served as the nonclinical safety lead on development programs. Heidi also authored toxicology and safety pharmacology modules for regulatory submissions. Prior to their time at Chimerix, Heidi worked at GSK as a director of investigative toxicology, where they managed the nonclinical safety strategy and budget for R&D programs. Heidi also served as a clinical safety scientist, conducting pharmacovigilance activities and coordinating regulatory document preparation. Heidi's early career at GSK involved roles in nonclinical safety assessment and toxicogenomics. Overall, Heidi's work experience spans both nonclinical and clinical aspects of drug development.

Heidi Colton attended Penn State University from 1992 to 1996, where they obtained a Bachelor of Science degree in Microbiology. Following this, they enrolled at North Carolina State University from 2000 to 2002. However, no specific degree or field of study information was provided for this period.